<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: The current study identified patients with either <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e> (ET) or <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>) who have survived for at least 20 yr without the development of either <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>/<z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e>) or <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> (MF) and compared their presenting features with those in whom these complications occurred in the first 10 yr of disease </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: The study patients were selected from an institutional database of 1061 patients with either ET (n = 603) or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> (n = 458) </plain></SENT>
<SENT sid="2" pm="."><plain>In both instances, three distinct groups were delineated and their presenting features compared; group A included patients who have remained <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e>/MF free after a minimum follow-up of 20 yr; groups B and C included patients who developed either <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> or MF, respectively, in the first decade of their disease </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The respective number of patients who fulfilled the above-mentioned criteria for inclusion in groups A, B and C were 40, 12 and 8 for ET and 23, 18 and 12 for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In ET, compared with both groups B and C, group A displayed significantly fewer patients with less than <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> level (P &lt; 0.0001 and =0.02) or male sex (P = 0.005 and 0.05), respectively </plain></SENT>
<SENT sid="5" pm="."><plain>On multivariable analysis, only <z:hpo ids='HP_0001903'>anemia</z:hpo> sustained its significance </plain></SENT>
<SENT sid="6" pm="."><plain>A similar analysis in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> revealed an association between group B and <z:hpo ids='HP_0001974'>leukocytosis</z:hpo> using a leukocyte count threshold of either 10 or 15 x 10(9)/L (P = 0.02) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: The current study identifies <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> patients with <z:hpo ids='HP_0001974'>leukocytosis</z:hpo> and ET patients with <z:hpo ids='HP_0001903'>anemia</z:hpo> as the most likely to undergo leukemic or fibrotic transformation </plain></SENT>
</text></document>